A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506517-22-00

Acronym

61186372GIC2002

Enrollment

Registered

2024-01-02

Start date

2022-08-31

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Colorectal Cancer

Brief summary

Objective response rate (ORR)

Interventions

DRUGIRINOTECAN

DRUGOXALIPLATIN

DRUG5-FU medac 50 mg/ml

DRUGInjektionslösung

DRUGRibofolin® 10 mg/ml Injektionslösung

DRUGFLUOROURACIL

DRUGOxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGJNJ-61186372

DRUGBENDAFOLIN 10 mg/ml Injektionslösung

DRUGIrinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGCALCIUM FOLINATE

DRUGFluorouracil Hikma 50 mg/ml Injektionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR)	—

Countries

Belgium, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026